XNASZYME
Market cap979mUSD
Jan 07, Last price
14.31USD
1D
-1.04%
1Q
12.41%
IPO
-36.12%
Name
Zymeworks Inc
Chart & Performance
P/E
—
P/S
12.89
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
18.81%
Rev. gr., 5y
7.47%
Revenues
76m
-81.57%
Net income
-119m
L
CFO
-118m
L
Earnings
Mar 04, 2025
Profile
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 76,012 -81.57% | 412,482 1,446.03% | |||||||
Cost of revenue | 357,008 | 490,657 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (280,996) | (78,175) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (568) | 10,893 | |||||||
Tax Rate | |||||||||
NOPAT | (280,428) | (89,068) | |||||||
Net income | (118,674) -195.44% | 124,341 -158.69% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 76,095 | 108,937 | |||||||
BB yield | -10.64% | -21.24% | |||||||
| Debt | |||||||||
Debt current | 30,109 | 3,322 | |||||||
Long-term debt | 49,183 | 52,904 | |||||||
Deferred revenue | 32,941 | 30,588 | |||||||
Other long-term liabilities | 1,609 | 2,977 | |||||||
Net debt | (377,183) | (436,892) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (118,303) | 144,109 | |||||||
CAPEX | (2,474) | (13,125) | |||||||
Cash from investing activities | (207,253) | (53,849) | |||||||
Cash from financing activities | 81,847 | 108,582 | |||||||
FCF | (270,321) | (86,948) | |||||||
| Balance | |||||||||
Cash | 374,327 | 492,232 | |||||||
Long term investments | 82,148 | 886 | |||||||
Excess cash | 452,674 | 472,494 | |||||||
Stockholders' equity | 322,532 | 341,342 | |||||||
Invested Capital | 203,546 | 196,208 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 68,863 | 65,249 | |||||||
Price | 10.39 32.19% | 7.86 -52.04% | |||||||
Market cap | 715,487 39.51% | 512,859 -39.98% | |||||||
EV | 338,304 | 75,967 | |||||||
EBITDA | (263,691) | (66,171) | |||||||
EV/EBITDA | |||||||||
Interest | 3,596 | ||||||||
Interest/NOPBT | |||||||||